Irish Health Repository >
Other Irish Health Organisations >
Charitable & Advocacy Organisations >
Our Lady's Hospice & Care Services >
Randomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNFα therapy medication.
|Files in This Item:|
|Title: ||Randomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNFα therapy medication.|
|Affiliation: ||Physiotherapy Department, Our Lady's Hospice and Care Services, Harold's Cross, Dublin, Ireland. email@example.com|
|Citation: ||Randomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNFα therapy medication. 2011, 12:11 BMC Musculoskelet Disord|
|Journal: ||BMC musculoskeletal disorders|
|Issue Date: ||2011 |
|PubMed ID: ||21232112|
|Abstract: ||Substantial progress has been made in the medical management of rheumatoid arthritis (RA) over the past decade with the introduction of biologic therapies, including anti-tumour necrosis factor alpha (anti-TNFα) therapy medications. However, individuals with RA taking anti-TNFα medication continue to experience physical, psychological and functional consequences, which could potentially benefit from rehabilitation. There is evidence that therapeutic exercise should be included as an intervention for people with RA, but to date there is little evidence of the benefits of therapeutic exercise for people with RA on anti-TNFα therapy medication. A protocol for a multicentre randomised controlled three-armed study which aims to examine the effect of dynamic group exercise therapy on land or in water for people with RA taking anti-TNFα therapy medication is described.|
Six hundred and eighteen individuals with RA, on anti-TNFα therapy medication, will be randomised into one of 3 groups: a land-based exercise group; a water-based exercise group or a control group. The land and water-based groups will exercise for one hour, twice a week for eight weeks. The control group will receive no intervention and will be asked not to alter their exercise habits for the duration of the study. The primary outcome measure, the Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) which measures functional ability, and secondary measures of pain, fatigue and quality of life, will be assessed at baseline, eight and 24 weeks by an independent assessor unaware of group allocation. Changes in outcome from 0 to 8 weeks and 0 to 24 weeks in the 'land-based exercise group versus control group' and the 'water-based exercise group versus control group' will be examined. Analysis will be conducted on an intention to treat basis.
This trial will evaluate the effectiveness of group exercise therapy on land or in water, for people with RA taking anti-TNFα therapy medication. If these exercise groups are found to be beneficial, they could be conducted in local community facilities thus making these forms of exercise more easily accessible for individuals and potentially reduce the burden on health services.
This trial is registered with ClinicalTrials.gov (a service of the United States National Institutes of Health) identifier: NCT00855322.
Tumor Necrosis Factor-alpha
|Appears in Collections: ||Our Lady's Hospice & Care Services|
this identifier to cite or link
to this item:
|Related articles on PubMed|
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators
2009 Jul 18
Land- and water-based exercise intervention in women with fibromyalgia: the al-Andalus physical activity randomised controlled trial.
Carbonell-Baeza A, Ruiz JR, Aparicio VA, Ortega FB, Munguía-Izquierdo D, Alvarez-Gallardo IC, Segura-Jiménez V, Camiletti-Moirón D, Romero A, Estévez-López F, Samos B, Casimiro AJ, Sierra Á, Latorre PA, Pulido-Martos M, Femia P, Pérez-López IJ, Chillón P, Girela-Rejón MJ, Tercedor P, Lucía A, Delgado-Fernández M
2012 Feb 15
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK
|See all 129 articles|
All Items in LENUS are protected by copyright, with all rights reserved, unless otherwise indicated.